NCT06470841View on ClinicalTrials.gov

CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

September 20, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

CHG Combined With Venetoclax and Azacytidine

"Patients were treated by CHG Combined With Venetoclax and Azacytidine:~Venetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-14; Azacytidine 75 mg/m2 subcutaneous injection qd d1-7; Homoharringtonine 1mg/m2 iv qd d1-14; Cytarabine 10mg/m2 subcutaneous injection q12h d1-14; G 250ug/m2 subcutaneous injection qd d0-14."

Trial Locations (1)

100048

Navy General Hospital, Beijing

All Listed Sponsors
lead

Navy General Hospital, Beijing

OTHER

NCT06470841 - CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML | Biotech Hunter | Biotech Hunter